Loading
Biohaven Pharmaceutical Holding Co Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Bailey Gregory, was filed 22 Aug 2022.
Biohaven Pharmaceutical Holding Co Ltd.: what insiders have been doing
Biohaven Pharmaceutical Holding Co Ltd., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Nothing new has been filed by managers of Biohaven Pharmaceutical Holding Co Ltd. in twelve months, the latest record being from 3 October 2022.
Our records for Biohaven Pharmaceutical Holding Co Ltd. go back to 2017, with 22 purchases and 296 sales on the open market in total.
Elsewhere in the same sector, our signals recently picked up insider purchases at Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
530
Thresholds
n/a
Buy Volume
€27M
22 ops. · all time
Sell Volume
€176M
296 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
Revenue411.7M
Gross profit330.1M80% margin
Net income-753.6M-183.0% margin
Last declaration on 3 October 2022
Declarations530 total
1,614 shares@ US$148.503.6% of flowCommon SharesSEC:0001562180-22-006956:1
313,500 shares@ US$148.5031.3% of flowCommon SharesSEC:0001562180-22-006963:1
19,130 shares@ US$148.501.9% of flowCommon SharesSEC:0001562180-22-006963:2
498,261 shares@ US$148.5049.7% of flowCommon SharesSEC:0001562180-22-006963:3
5,374 shares@ US$148.507.8% of flowCommon SharesSEC:0001562180-22-006951:1
10,000 shares@ US$148.500.3% of flowCommon SharesSEC:0001562180-22-006964:1
15,900 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006955:0
2,900 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006961:0
11,653 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006949:0
3,025,001 shares@ US$148.5099.9% of flowCommon SharesSEC:0001562180-22-006964:0
5,068 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006956:0
11,090 shares@ US$148.5096.4% of flowCommon SharesSEC:0001562180-22-006951:0
4,292 shares@ US$148.5053.7% of flowCommon SharesSEC:0001562180-22-006952:0
14,226 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006962:0
2,583,658 shares@ US$148.5098.6% of flowCommon SharesSEC:0001562180-22-006953:0
6,177 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006959:0
92,050 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006963:0
22,362 shares@ US$148.5091.0% of flowCommon SharesSEC:0001562180-22-006950:0
10,640 shares@ US$148.50100.0% of flowCommon SharesSEC:0001562180-22-006958:0
38,000 shares@ US$148.04411.4% of flowCommon StockSEC:0001562180-22-006259:0
Canonical exit: 17 Nov 2022 (T+90)
4,200 shares@ US$141.5017.7% of flowCommon SharesSEC:0001562180-22-004014:1
2,250 shares@ US$53.769.5% of flowCommon SharesSEC:0001562180-22-004014:0
13,334 shares@ US$68.15Common SharesSEC:0001562180-22-001435:1
15,508 shares@ US$68.58Common SharesSEC:0001562180-22-001435:2
10,000 shares@ US$68.97Common SharesSEC:0001562180-22-001435:3
25 of 530 declarations
About Biohaven Pharmaceutical Holding Co Ltd.
Biohaven Ltd. is a U.S.-listed biopharmaceutical company traded on the NYSE under the ticker BHVN. Its headquarters are in New Haven, Connecticut, placing it in a major U.S. life-sciences hub with close historical ties to Yale and the Northeast biotech ecosystem. The company as it exists today is relatively recent: it was formed following a spin-off completed in October 2022 from the former Biohaven Pharmaceutical Holding Company Ltd. Biohaven describes itself as a global clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for both rare and common diseases, with an emphasis on platform-driven innovation rather than a large portfolio of established marketed drugs.([ir.biohaven.com](https://ir.biohaven.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-fourth-0?utm_source=openai))
The company’s business model is centered on multiple R&D franchises, including migraine, targeted extracellular protein degraders, antibody-drug conjugates (ADCs), and other early- to mid-stage assets. Biohaven initially built market recognition in migraine through Nurtec ODT (rimegepant) and Zavzpret (zavegepant), which helped establish its clinical and commercial credibility in a highly competitive therapeutic area. Today, management emphasizes a broader platform strategy, especially its MoDE and TRAP degrader technologies, which are designed to selectively degrade extracellular proteins, alongside next-generation ADC efforts. This portfolio expansion broadens Biohaven’s potential beyond migraine into immunology, inflammation, rare disease, and selected neuroscience opportunities.([biohaven.com](https://www.biohaven.com/?utm_source=openai))
Read moreShow less
From a competitive standpoint, Biohaven remains a classic clinical biotech story: high upside, but with meaningful dependence on trial execution, regulatory outcomes, and capital allocation. Its profile is that of a research-intensive company whose valuation is driven by pipeline quality and data readouts rather than near-term earnings power. Recent company updates indicate that in 2025 Biohaven restructured priorities to reduce direct R&D spending and concentrate resources on the most attractive programs. Among the latest notable developments, Biohaven reported quarterly results and business updates in March and May 2026, including progress on BHV-1530, a first-in-class FGFR3-directed ADC, and further advancement of its proprietary degrader platform. The company also points to collaboration activity, which may help share scientific and development risk. For investors, BHVN represents a typical U.S. biotech opportunity: substantial long-term optionality, but limited visibility and high sensitivity to clinical and regulatory catalysts.([ir.biohaven.com](https://ir.biohaven.com/news-releases/news-release-details/biohaven-reports-recent-business-developments-and-first-quarter?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
